aztreonam has been researched along with Body Weight in 4 studies
Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aztreonam is a monocyclic β-lactam antibiotic often used to treat infections caused by Enterobacteriaceae or Pseudomonas aeruginosa." | 1.46 | Evaluation of Aztreonam Dosing Regimens in Patients With Normal and Impaired Renal Function: A Population Pharmacokinetic Modeling and Monte Carlo Simulation Analysis. ( Al-Huniti, N; Li, J; Xu, H; Zhou, D; Zhou, W, 2017) |
| " In order to evaluate the difficulties, a pharmacokinetic analysis of aztreonam (AZT), which is a monocyclic beta-lactam antimicrobial agent, was undertaken in 2 groups consisting of 5 children of ages 1-6 and 5 older children of 7-15." | 1.28 | [Dose calibration of aztreonam in pediatric patients by means of pharmacokinetic analysis]. ( Kawasaki, H, 1991) |
| "Interspecies correlations of pharmacokinetic parameters obtained in animals were used to predict human pharmacokinetics in order to design the first clinical study of an investigational drug." | 1.27 | Prediction of aztreonam pharmacokinetics in humans based on data from animals. ( Bonner, DP; Swabb, EA, 1983) |
| "Aztreonam (SQ 26,776) was given subcutaneously to three groups of neonatal rats at daily doses of 150, 600, and 2400 mg/kg from postnatal Days 10 through 16." | 1.27 | Ototoxicity of subcutaneously administered aztreonam in neonatal rats. ( DePaoli, A; Keim, GR; Myhre, JL, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, H | 1 |
| Zhou, W | 1 |
| Zhou, D | 1 |
| Li, J | 1 |
| Al-Huniti, N | 1 |
| Swabb, EA | 1 |
| Bonner, DP | 1 |
| Kawasaki, H | 1 |
| Myhre, JL | 1 |
| DePaoli, A | 1 |
| Keim, GR | 1 |
4 other studies available for aztreonam and Body Weight
| Article | Year |
|---|---|
Evaluation of Aztreonam Dosing Regimens in Patients With Normal and Impaired Renal Function: A Population Pharmacokinetic Modeling and Monte Carlo Simulation Analysis.
Topics: Adult; Age Factors; Anti-Bacterial Agents; Aztreonam; Body Height; Body Weight; Clinical Trials as T | 2017 |
Prediction of aztreonam pharmacokinetics in humans based on data from animals.
Topics: Animals; Anti-Bacterial Agents; Aztreonam; Body Weight; Humans; Kinetics; Macaca fascicularis; Mice; | 1983 |
[Dose calibration of aztreonam in pediatric patients by means of pharmacokinetic analysis].
Topics: Age Factors; Aztreonam; Body Height; Body Weight; Calibration; Child; Child, Preschool; Female; Huma | 1991 |
Ototoxicity of subcutaneously administered aztreonam in neonatal rats.
Topics: Animals; Animals, Newborn; Anti-Bacterial Agents; Aztreonam; Body Weight; Ear Diseases; Female; Inje | 1985 |